US 7,589,208 B2
Compositions containing quinoline compounds
Karl Jansson, Dalby (Sweden); Tomas Fristedt, Helsingborg (Sweden); Hans Wännman, Ängelholm (Sweden); and Anders Björk, Bjärred (Sweden)
Assigned to Active Biotech AB, Lund (Sweden)
Filed on Feb. 04, 2005, as Appl. No. 11/50,441.
Claims priority of application No. 0400235 (SE), filed on Feb. 06, 2004.
Prior Publication US 2005/0192315 A1, Sep. 01, 2005
Int. Cl. C07D 215/38 (2006.01)
U.S. Cl. 546—155  [546/159; 546/153] 32 Claims
 
1. A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II)

OG Complex Work Unit Drawing
wherein n is an integer of 1, 2 or 3; An+ is a mono- or multivalent metal cation selected from Li+, Na+, K+, Mg2+, Ca2+, Mn2+, Cu2+, Zn2+, Al3+and Fe3+;
R is a straight or branched C1-C4-alkyl or -alkenyl or a cyclic C3-C4-alkyl;
R5 is a straight or branched, saturated or unsaturated C1-C4-alkyl or -alkenyl, a cyclic C3-C4-alkyl, a straight or branched C1-C4-alkylthio, a cyclic C3-C4-alkylthio, a straight or branched C1-C4-alkylsulfinyl, a cyclic C3-C4-alkylsulfinyl, fluoro, chloro, bromo, trifluoromethyl or trifluoromethoxy; and
R6 is hydrogen; or
R5 and R6 taken together are methylenedioxy;
R′ is hydrogen, a straight or branched, saturated or unsaturated C1-C4-alkyl or -alkenyl, a cyclic C3-C4-alkyl, a straight or branched C1-C4-alkoxy, a cyclic C3-C4-alkoxy, fluoro, chloro, bromo or trifluoromethyl; and
R″ is hydrogen, fluoro or chloro, with the proviso that R″ is fluoro or chloro only when R′ is fluoro or chloro;
an alkaline-reacting component, or a salt with a divalent metal cation; and
at least one pharmaceutical excipient;
wherein said salt of formula (II) is essentially stable during storage at room temperature for a period of at least 3 years.